QUICK SNAPSHOT

DSIP

Sleep & Neuromodulation

FDA Status
Not FDA-Approved
Claimed Benefits
  • Sleep regulation (mixed evidence)
  • Chronic pain reduction (pilot)
  • Neuroendocrine modulation
Clinical Evidence
4
Human Trials
Phase II
Highest Phase

A rigorous 1992 double-blind trial concluded DSIP's sleep effects were weak and likely placebo-driven.

Read Full Deep Dive

Mechanism, dosing, vendor pricing, and full research citations

Monthly Digest

Stay ahead of the market

New peptide profiles, vendor pricing shifts, and research updates. No spam, unsubscribe anytime.